GEMCITABINE

作品数：313被引量：907H指数：11
导出分析报告
相关领域：医药卫生更多>>
相关作者：贾林巴一黄鼎智韩如冰李鸿立更多>>
相关机构：中山大学广州医学院天津医科大学广州市第一人民医院更多>>
相关期刊：更多>>
相关基金：国家自然科学基金中国博士后科学基金广东省社会发展领域科技计划项目国家重点基础研究发展计划更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Idarubicin-transarterial chemoembolization combined with gemcitabine plus cisplatin for unresectable intrahepatic cholangiocarcinoma
《World Journal of Gastrointestinal Oncology》2025年第4期81-92,共12页Cheng-Hao Zhao Huan Liu Tao Pan Zhan-Wang Xiang Lu-Wen Mu Jun-Yang Luo Chu-Ren Zhou Ming-An Li Ming-Ming Liu Hu-Zheng Yan Ming-Sheng Huang 
Supported by the Guangzhou Science and Technology Plan Project,No.2023A04J0419;National Natural Science Foundation Cultivation Project at the Third Affiliated Hospital of Sun Yat-sen University,No.2022GZRPYQN04.
BACKGROUND Intrahepatic cholangiocarcinoma(iCCA)is the second most common liver malignancy with poor prognosis and limited treatment options.AIM To identify the most effective drug for transarterial chemoembolization(...
关键词：Transarterial chemoembolization Intrahepatic cholangiocarcinoma GEMCITABINE CISPLATIN IDARUBICIN 
SLFN11 Deficiency-Induced Gemcitabine Resistance Is Overcome by Agents Targeting the DNA Damage Response in Pancreatic Cancer Cells
《BIOCELL》2025年第4期681-700,共20页Jae Hyeong Kim Yuna Youn Jin-Hyeok Hwang 
supported by the 8th AstraZeneca-KHIDI(Korea Health Industry Development Institute)oncology research program;a research grant was supported by AstraZeneca and by Grant No.02-2022-0020 from the Seoul National University Hospital(SNUBH)Research Fund.
Objectives:SLFN11(Schlafen-11)enhances sensitivity to DNA-damaging agents(DDAs)and DNA damage response(DDR)inhibitors in various cancer types.However,its function in pancreatic cancer(PC)remains largely unknown.This r...
关键词：SLFN11 DNA-damaging agents DNA damage response pancreatic cancer 
Exosome technology:A novel and effective drug delivery system in the field of cancer therapy
《World Journal of Gastrointestinal Oncology》2025年第3期464-469,共6页Jia-Xin Geng Yao-Fan Lu Jing-Nan Zhou Biao Huang Yuan Qin 
Natural Science Foundation of Zhejiang Province,No.LQ23H050005;Zhejiang Medical and Health Science and Technology Project,No.2023KY615;Scientific Research Project of Zhejiang Provincial Education Department,No.Y202250731 and No.Y202353130;the China Students’Innovation and Entrepreneurship Training Program,No.202310338044;China Postdoctoral Science Foundation,No.2022M721720.
In this article,we revisit an article,which specifically focuses on the utilization of exosomes derived from human bone marrow mesenchymal stem cells(MSCs)for targeted delivery of gemcitabine in pancreatic cancer trea...
关键词：EXOSOMES Drug delivery Mesenchymal stem cells Tumor therapy GEMCITABINE 
Programmed cell death 1 inhibitor sintilimab plus S-1 and gemcitabine for liver metastatic pancreatic ductal adenocarcinoma
《World Journal of Clinical Oncology》2025年第2期29-35,共7页Shi-Qiong Zhou Peng Wan Seng Zhang Yuan Ren Hong-Tao Li Qing-Hua Ke 
BACKGROUND Pancreatic ductal adenocarcinoma(PDAC)is a highly aggressive cancer with poor prognosis.When it metastasizes to the liver,treatment options become particularly limited and challenging.Current treatment opti...
关键词：IMMUNOTHERAPY Programmed cell death 1 inhibitor Sintilimab Chemotherapy METASTATIC Pancreatic ductal adenocarcinoma 
G3BP2 promotes tumor progression and gemcitabine resistance in PDAC via regulating PDIA3-DKC1-hENT in a stress granules-dependent manner
《Acta Pharmacologica Sinica》2025年第2期474-488,共15页Fa-liang Xing Bo-rui Li Ying-jin Fang Chen Liang Jiang Liu Wei Wang Jin Xu Xian-jun Yu Yi Qin Bo Zhang 
supported by the National Natural Science Foundation of China(82173178,82173281,U21A20374,and 82072698);Shanghai Municipal Science and Technology Major Project(21JC1401500);Scientific Innovation Project of Shanghai Education Committee(2019-01-07-00-07-E00057);Natural Science Foundation of Shanghai Municipal Science and Technology Committee(21ZR1415200);Natural Science Foundation of Shanghai(23ZR1479300).
Pancreatic ductal adenocarcinoma(PDAC)is distinguished by its aggressive malignancy,limited treatment avenues and a tendency towards chemotherapy resistance,underscoring the critical need for advanced research to unco...
关键词：pancreatic ductal adenocarcinoma gemcitabine resistance G3BP2 PDIA3-DKC1-hENT stress granules 
Exosomes as promising frontier approaches in future cancer therapy
《World Journal of Gastrointestinal Oncology》2025年第1期28-33,共6页Fatt-Yang Chew Chin-Hung Tsai Kuang-Hsi Chang Yu-Kang Chang Ruey-Hwang Chou Yi-Jui Liu 
Supported by the grants of China Medical University Hospital,No.DMR-112-173 and No.DMR-113-089;the grant from Tungs’Taichung Metro Harbor Hospital,No.TTMHH-R1120013.
In this editorial,we will discuss the article by Tang et al published in the recent issue of the World Journal of Gastrointestinal Oncology.They explored an innovative approach to enhancing gemcitabine(GEM)delivery an...
关键词：Mesenchymal stem cells EXOSOMES GEMCITABINE Pancreatic cancer APOPTOSIS 
Complete response of gallbladder cancer treated with gemcitabine and cisplatin chemotherapy combined with durvalumab:A case report and review of literature
《World Journal of Gastrointestinal Oncology》2025年第1期226-232,共7页Kai Chen Xu Feng Yuan Shi Xin-Lin Li Zheng-Rong Shi Xiang Lan 
Supported by General Project of Natural Science Foundation of Chongqing,China,No.cstc2021jcyj-msxmX0604;Chongqing Doctoral"Through Train"Research Program,China,No.CSTB2022BSXM-JCX0045.
BACKGROUND Gallbladder cancer(GBC)is the most common and aggressive subtype of biliary tract cancer(BTC)and has a poor prognosis.A newly developed regimen of gemcitabine,cisplatin,and durvalumab shows promise for the ...
关键词：Gallbladder cancer CHEMOTHERAPY IMMUNOTHERAPY Durvalumab Complete response Case report 
Synergistic effects of resveratrol with gemcitabine in pancreatic cancer chemotherapy by inhibiting the c-Met/PARP1 axis
《Journal of Pancreatology》2024年第4期267-278,共12页Shuai Wu Jiaqiang Ren Weikun Qian Mengyuan Gong Jie Li Tao Qin Simei Zhang Wunai Zhang Hao Sun Zheng Wu Zheng Wang Qingyong Ma Wanxing Duan 
supported by grants from the National Natural Science Foundation of China (No.82072699);the Natural Science Basic Research Program of Shaanxi Province,China (Nos.2023-JC-ZD-54 and 2017JM8165).
Objective:Pancreatic cancer is a highly malignant tumor of the digestive tract with a dismal prognosis.A key challenge of pancreatic cancer is its resistance to chemotherapy.The C-mesenchymal-epithelial transition fac...
关键词：CHEMORESISTANCE GEMCITABINE Pancreatic cancer RESVERATROL Synergistic effects 
Large-Scale Machine Learning Analysis Reveals DNA Methylation and Gene Expression Response Signatures for Gemcitabine-Treated Pancreatic Cancer
《Health Data Science》2024年第1期406-419,共14页Adeolu Ogunleye Chayanit Piyawajanusorn Ghita Ghislat Pedro J.Ballester 
supported by the Petroleum Technology Development Fund(Nigeria,PTDF/ED/PHD/APO/27/18);the Commemoration of Her Royal Highness Princess Chulabhorn’s 60th Birthday Anniversary scholarship from Chulabhorn Royal Academy(TTailand);the Marie-Curie actions IEF-Horizon(EU,LCII_PA4887);the Wolfson Foundation and the Royal Society for a Royal Society Wolfson Fellowship(UK,RSWF\R1\221005)。
Background:Gemcitabine is a first-line chemotherapy for pancreatic adenocarcinoma(PAAD),but many PAAD patients do not respond to gemcitabine-containing treatments.Being able to predict such nonresponders would hence p...
关键词：hence SPITE release 
LncRNA AFAP1-AS1 exhibits oncogenic characteristics and promotes gemcitabine-resistance of cervical cancer cells through miR-7-5p/EGFR axis
《Oncology Research》2024年第12期1867-1879,共13页CHAOQUN WANG TING ZHANG CHAOHE ZHANG 
Background:Drug resistance is the main factor contributing to cancer recurrence and poor prognosis.Exploration of drug resistance-related mechanisms and effective therapeutic targets are the aim of molecular targeted ...
关键词：Long non-coding RNA(lncRNA)AFAP1-AS1 miR-7-5p Epidermal growth factor receptor(EGFR) Gemcitabine-resistance Cervical cancer 
全选清除导出
共32页<12345678910>
检索报告 对象比较 聚类工具 使用帮助 返回顶部